;PMID: 9332768
;source_file_525.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..54] = [t:0..54]
;1)sentence:[e:59..127] = [t:59..127]
;2)section:[e:131..208] = [t:131..208]
;3)section:[e:212..353] = [t:212..353]
;4)sentence:[e:357..428] = [t:357..428]
;5)sentence:[e:429..522] = [t:429..522]
;6)sentence:[e:523..585] = [t:523..585]
;7)sentence:[e:586..653] = [t:586..653]
;8)sentence:[e:654..740] = [t:654..740]
;9)sentence:[e:741..885] = [t:741..885]
;10)sentence:[e:886..1073] = [t:886..1073]
;11)sentence:[e:1074..1145] = [t:1074..1145]
;12)sentence:[e:1146..1246] = [t:1146..1246]
;13)sentence:[e:1247..1376] = [t:1247..1376]
;14)sentence:[e:1377..1549] = [t:1377..1549]
;15)sentence:[e:1550..1796] = [t:1550..1796]
;16)sentence:[e:1797..1880] = [t:1797..1880]
;17)sentence:[e:1881..1973] = [t:1881..1973]
;18)section:[e:1974..2308] = [t:1974..2308]
;19)section:[e:2312..2356] = [t:2312..2356]

;section 0 Span:0..54
;Cancer Epidemiol Biomarkers Prev  1997 Oct;6(10):841-7
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..16] Epidemiol) (NNP:[17..27] Biomarkers)
        (NNP:[28..32] Prev) (CD:[34..38] 1997) (CC:[39..43] Oct;)
        (CD:[43..44] 6) (NN:[44..45] -LRB-) (NN:[45..47] 10) (NN:[47..48] -RRB-)
        (IN:[48..49] :) (CD:[49..51] 84) (CD:[51..54] 1-7)))

;sentence 1 Span:59..127
;Prognostic value of specific KRAS mutations in lung adenocarcinomas.
;[88..92]:gene-rna:"KRAS"
;[106..126]:malignancy:"lung adenocarcinomas"
(SENT
  (NP-HLN
    (NP (JJ:[59..69] Prognostic) (NN:[70..75] value))
    (PP (IN:[76..78] of)
      (NP (JJ:[79..87] specific) (NN:[88..92] KRAS) (NNS:[93..102] mutations)))
    (PP-LOC (IN:[103..105] in)
      (NP (NN:[106..110] lung) (NNS:[111..126] adenocarcinomas)))
    (.:[126..127] .)))

;section 2 Span:131..208
;Siegfried JM, Gillespie AT, Mera R, Casey TJ, Keohavong P, Testa JR, Hunt
;JD.
(SEC
  (FRAG (NNP:[131..140] Siegfried) (NNP:[141..143] JM) (,:[143..144] ,)
        (NNP:[145..154] Gillespie) (NNP:[155..157] AT) (,:[157..158] ,)
        (NNP:[159..163] Mera) (NNP:[164..165] R) (,:[165..166] ,)
        (NNP:[167..172] Casey) (NNP:[173..175] TJ) (,:[175..176] ,)
        (NNP:[177..186] Keohavong) (NNP:[187..189] P,) (NNP:[190..195] Testa)
        (NNP:[196..198] JR) (,:[198..199] ,) (NNP:[200..204] Hunt)
        (.:[205..208] JD.)))

;section 3 Span:212..353
;Department of Pharmacology, University of Pittsburgh School of Medicine, 
;University of Pittsburgh Cancer Institute, Pennsylvania 15261, USA.
(SEC
  (FRAG (NNP:[212..222] Department) (IN:[223..225] of)
        (NNP:[226..238] Pharmacology) (,:[238..239] ,)
        (NNP:[240..250] University) (IN:[251..253] of)
        (NNP:[254..264] Pittsburgh) (NNP:[265..271] School) (IN:[272..274] of)
        (NNP:[275..283] Medicine) (,:[283..284] ,) (NNP:[286..296] University)
        (IN:[297..299] of) (NNP:[300..310] Pittsburgh) (NNP:[311..317] Cancer)
        (NNP:[318..327] Institute) (,:[327..328] ,)
        (NNP:[329..341] Pennsylvania) (VBD:[342..347] 15261) (,:[347..348] ,)
        (NNP:[349..352] USA) (.:[352..353] .)))

;sentence 4 Span:357..428
;Adenocarcinomas of the lung remain a significant public health problem.
;[357..384]:malignancy:"Adenocarcinomas of the lung"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[357..372] Adenocarcinomas))
      (PP (IN:[373..375] of)
        (NP (DT:[376..379] the) (NN:[380..384] lung))))
    (VP (VBP:[385..391] remain)
      (NP-PRD (DT:[392..393] a) (JJ:[394..405] significant)
        (NML (JJ:[406..412] public) (NN:[413..419] health))
        (NN:[420..427] problem)))
    (.:[427..428] .)))

;sentence 5 Span:429..522
;Locally  defined (stage I) tumors are considered amenable to resection with
;curative  intent.
;[429..462]:malignancy:"Locally  defined (stage I) tumors"
(SENT
  (S
    (NP-SBJ-1
      (ADJP (RB:[429..436] Locally) (JJ:[438..445] defined)
        (PRN (-LRB-:[446..447] -LRB-)
          (NP (NN:[447..452] stage) (CD:[453..454] I))
          (-RRB-:[454..455] -RRB-)))
      (NNS:[456..462] tumors))
    (VP (VBP:[463..466] are)
      (VP (VBN:[467..477] considered)
        (S
          (NP-SBJ-1 (-NONE-:[477..477] *))
          (ADJP-PRD (JJ:[478..486] amenable)
            (PP (TO:[487..489] to)
              (NP
                (NP (NN:[490..499] resection))
                (PP (IN:[500..504] with)
                  (NP (JJ:[505..513] curative) (NN:[515..521] intent)))))))))
    (.:[521..522] .)))

;sentence 6 Span:523..585
;However, only about 45% of these patients survive for 5 years.
(SENT
  (S
    (ADVP (RB:[523..530] However))
    (,:[530..531] ,)
    (NP-SBJ
      (NP (RB:[532..536] only)
        (QP (RB:[537..542] about) (CD:[543..545] 45))
        (NN:[545..546] %))
      (PP (IN:[547..549] of)
        (NP (DT:[550..555] these) (NNS:[556..564] patients))))
    (VP (VBP:[565..572] survive)
      (PP-TMP (IN:[573..576] for)
        (NP (CD:[577..578] 5) (NNS:[579..584] years))))
    (.:[584..585] .)))

;sentence 7 Span:586..653
;The  median survival for more advanced tumors is drastically lower.
;[611..631]:malignancy:"more advanced tumors"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[586..589] The) (JJ:[591..597] median) (NN:[598..606] survival))
      (PP (IN:[607..610] for)
        (NP (RBR:[611..615] more) (JJ:[616..624] advanced)
            (NNS:[625..631] tumors))))
    (VP (VBZ:[632..634] is)
      (ADJP-PRD (RB:[635..646] drastically) (JJR:[647..652] lower)))
    (.:[652..653] .)))

;sentence 8 Span:654..740
;Much research has  been focused on identifying a valid genetic biomarker of
;prognosis.
(SENT
  (S
    (NP-SBJ-1 (JJ:[654..658] Much) (NN:[659..667] research))
    (VP (VBZ:[668..671] has)
      (VP (VBN:[673..677] been)
        (VP (VBN:[678..685] focused)
          (NP-1 (-NONE-:[685..685] *))
          (PP (IN:[686..688] on)
            (S-NOM
              (NP-SBJ (-NONE-:[688..688] *))
              (VP (VBG:[689..700] identifying)
                (NP
                  (NP (DT:[701..702] a) (JJ:[703..708] valid)
                      (JJ:[709..716] genetic) (NN:[717..726] biomarker))
                  (PP (IN:[727..729] of)
                    (NP (NN:[730..739] prognosis))))))))))
    (.:[739..740] .)))

;sentence 9 Span:741..885
;Mutations of  the proto-oncogene KRAS have been identified by some groups as
;being a valid  prognostic indicator for adenocarcinoma of the lung.
;[774..778]:gene-rna:"KRAS"
;[858..884]:malignancy:"adenocarcinoma of the lung"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[741..750] Mutations))
      (PP (IN:[751..753] of)
        (NP
          (NP (DT:[755..758] the) (AFX:[759..764] proto) (HYPH:[764..765] -)
              (NN:[765..773] oncogene))
          (NP (NN:[774..778] KRAS)))))
    (VP (VBP:[779..783] have)
      (VP (VBN:[784..788] been)
        (VP (VBN:[789..799] identified)
          (NP-1 (-NONE-:[799..799] *))
          (PP (IN:[800..802] by)
            (NP-LGS (DT:[803..807] some) (NNS:[808..814] groups)))
          (PP (IN:[815..817] as)
            (S-NOM
              (NP-SBJ (-NONE-:[817..817] *))
              (VP (VBG:[818..823] being)
                (NP-PRD
                  (NP (DT:[824..825] a) (JJ:[826..831] valid)
                      (JJ:[833..843] prognostic) (NN:[844..853] indicator))
                  (PP (IN:[854..857] for)
                    (NP
                      (NP (NN:[858..872] adenocarcinoma))
                      (PP (IN:[873..875] of)
                        (NP (DT:[876..879] the) (NN:[880..884] lung))))))))))))
    (.:[884..885] .)))

;sentence 10 Span:886..1073
;To evaluate the effect of  KRAS gene mutation on the survival of patients
;with lung adenocarcinoma, 181  archival tumors were examined by PCR and
;denaturing gradient gel  electrophoresis.
;[913..917]:gene-rna:"KRAS"
;[965..984]:malignancy:"lung adenocarcinoma"
;[991..1006]:malignancy:"archival tumors"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[886..886] *))
      (VP (TO:[886..888] To)
        (VP (VB:[889..897] evaluate)
          (NP
            (NP (DT:[898..901] the) (NN:[902..908] effect))
            (PP (IN:[909..911] of)
              (NP (NN:[913..917] KRAS) (NN:[918..922] gene)
                  (NN:[923..931] mutation)))
            (PP (IN:[932..934] on)
              (NP
                (NP (DT:[935..938] the) (NN:[939..947] survival))
                (PP (IN:[948..950] of)
                  (NP (NNS:[951..959] patients)))
                (PP (IN:[960..964] with)
                  (NP (NN:[965..969] lung) (NN:[970..984] adenocarcinoma)))))))))
    (,:[984..985] ,)
    (NP-SBJ-1 (CD:[986..989] 181)
       (JJ:[991..999] archival) (NNS:[1000..1006] tumors))
    (VP (VBD:[1007..1011] were)
      (VP (VBN:[1012..1020] examined)
        (NP-1 (-NONE-:[1020..1020] *))
        (PP-MNR (IN:[1021..1023] by)
          (NP
            (NP (NN:[1024..1027] PCR))
            (CC:[1028..1031] and)
            (NP
              (NML (VBG:[1032..1042] denaturing) (NN:[1043..1051] gradient))
              (NN:[1052..1055] gel) (NN:[1057..1072] electrophoresis))))))
    (.:[1072..1073] .)))

;sentence 11 Span:1074..1145
;Mutations in either codon 12 or 13 were found in 31.5% of the  samples.
;[1074..1083]:variation-event:"Mutations"
;[1094..1102]:variation-location:"codon 12"
;[1094..1099]...[1106..1108]:variation-location:"codon"..."13"
(SENT
  (S
    (NP-SBJ-2
      (NP (NNS:[1074..1083] Mutations))
      (PP-LOC (IN:[1084..1086] in)
        (NP (CC:[1087..1093] either)
          (NP
            (NML-1 (NN:[1094..1099] codon))
            (CD:[1100..1102] 12))
          (CC:[1103..1105] or)
          (NP
            (NML-1 (-NONE-:[1105..1105] *P*))
            (CD:[1106..1108] 13)))))
    (VP (VBD:[1109..1113] were)
      (VP (VBN:[1114..1119] found)
        (NP-2 (-NONE-:[1119..1119] *))
        (PP-LOC (IN:[1120..1122] in)
          (NP
            (NP (CD:[1123..1127] 31.5) (NN:[1127..1128] %))
            (PP (IN:[1129..1131] of)
              (NP (DT:[1132..1135] the) (NNS:[1137..1144] samples)))))))
    (.:[1144..1145] .)))

;sentence 12 Span:1146..1246
;The most common mutation was a G-->T transversion in codon 12,  representing
;66.7% of the mutations.
;[1162..1170]:variation-event:"mutation"
;[1177..1178]:variation-state-original:"G"
;[1181..1182]:variation-state-altered:"T"
;[1183..1195]:variation-type:"transversion"
;[1199..1207]:variation-location:"codon 12"
;[1236..1245]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ (DT:[1146..1149] The) (RBS:[1150..1154] most)
            (JJ:[1155..1161] common) (NN:[1162..1170] mutation))
    (VP (VBD:[1171..1174] was)
      (NP-PRD
        (NP (DT:[1175..1176] a)
          (NML
            (NML (NN:[1177..1178] G))
            (PP (SYM:[1178..1181] -->)
              (NP (NN:[1181..1182] T))))
          (NN:[1183..1195] transversion))
        (PP-LOC (IN:[1196..1198] in)
          (NP (NN:[1199..1204] codon) (CD:[1205..1207] 12))))
      (,:[1207..1208] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1208..1208] *))
        (VP (VBG:[1210..1222] representing)
          (NP
            (NP (CD:[1223..1227] 66.7) (NN:[1227..1228] %))
            (PP (IN:[1229..1231] of)
              (NP (DT:[1232..1235] the) (NNS:[1236..1245] mutations)))))))
    (.:[1245..1246] .)))

;sentence 13 Span:1247..1376
;No difference was observed in the survival  of patients with a KRAS mutation
;versus those whose tumors contained wild-type  KRAS.
;[1310..1314]:gene-rna:"KRAS"
;[1343..1349]:malignancy:"tumors"
;[1371..1375]:gene-rna:"KRAS"
(SENT
  (S
    (NP-SBJ-2 (DT:[1247..1249] No) (NN:[1250..1260] difference))
    (VP (VBD:[1261..1264] was)
      (VP (VBN:[1265..1273] observed)
        (NP-2 (-NONE-:[1273..1273] *))
        (PP (IN:[1274..1276] in)
          (NP
            (NP
              (NP (DT:[1277..1280] the) (NN:[1281..1289] survival))
              (PP (IN:[1291..1293] of)
                (NP
                  (NP (NNS:[1294..1302] patients))
                  (PP (IN:[1303..1307] with)
                    (NP (DT:[1308..1309] a) (NN:[1310..1314] KRAS)
                        (NN:[1315..1323] mutation))))))
            (IN:[1324..1330] versus)
            (NP
              (NP (DT:[1331..1336] those))
              (SBAR
                (WHNP-1 (WP$:[1337..1342] whose) (NNS:[1343..1349] tumors))
                (S
                  (NP-SBJ-1 (-NONE-:[1349..1349] *T*))
                  (VP (VBD:[1350..1359] contained)
                    (NP (JJ:[1360..1369] wild-type) (NN:[1371..1375] KRAS))))))))))
    (.:[1375..1376] .)))

;sentence 14 Span:1377..1549
;This lack of difference was also observed when the analysis was restricted 
;to those with stage I tumors or when patients with stage I or II disease were
; grouped together.
;[1467..1481]:malignancy:"stage I tumors"
;[1504..1511]:malignancy:"stage I"
;[1515..1525]:malignancy:"II disease"
(SENT
  (S
    (NP-SBJ-7
      (NP (DT:[1377..1381] This) (NN:[1382..1386] lack))
      (PP (IN:[1387..1389] of)
        (NP (NN:[1390..1400] difference))))
    (VP (VBD:[1401..1404] was)
      (ADVP (RB:[1405..1409] also))
      (VP (VBN:[1410..1418] observed)
        (NP-7 (-NONE-:[1418..1418] *))
        (SBAR-ADV
          (SBAR
            (WHADVP-6 (WRB:[1419..1423] when))
            (S
              (NP-SBJ-1 (DT:[1424..1427] the) (NN:[1428..1436] analysis))
              (VP (VBD:[1437..1440] was)
                (VP (VBN:[1441..1451] restricted)
                  (NP-1 (-NONE-:[1451..1451] *))
                  (PP-CLR (TO:[1453..1455] to)
                    (NP
                      (NP (DT:[1456..1461] those))
                      (PP (IN:[1462..1466] with)
                        (NP
                          (NML (NN:[1467..1472] stage) (CD:[1473..1474] I))
                          (NNS:[1475..1481] tumors)))))
                  (ADVP-6 (-NONE-:[1481..1481] *T*))))))
          (CC:[1482..1484] or)
          (SBAR
            (WHADVP-5 (WRB:[1485..1489] when))
            (S
              (NP-SBJ-4
                (NP (NNS:[1490..1498] patients))
                (PP (IN:[1499..1503] with)
                  (NP
                    (NP
                      
                      (NML-2 (NN:[1504..1509] stage))
                      (CD:[1510..1511] I)
                      (NML-3 (-NONE-:[1511..1511] *P*)))
                    (CC:[1512..1514] or)
                    (NP
                      (NML-2 (-NONE-:[1514..1514] *P*))
                       (CD:[1515..1517] II)
                      (NML-3 (NN:[1518..1525] disease))))))
              (VP (VBD:[1526..1530] were)
                (VP (VBN:[1532..1539] grouped)
                  (NP-4 (-NONE-:[1539..1539] *))
                  (ADVP (RB:[1540..1548] together))
                  (ADVP-TMP-5 (-NONE-:[1548..1548] *T*)))))))))
    (.:[1548..1549] .)))

;sentence 15 Span:1550..1796
;However, certain amino acid substitutions, including cysteine,  arginine, and
;aspartate, indicated a significantly poorer prognosis, whereas  hydrophobic
;amino acid substitutions showed a significantly better prognosis  than
;wild-type (P = 0.04).
;[1578..1591]:variation-type:"substitutions"
;[1603..1611]:variation-state-generic:"cysteine"
;[1614..1622]:variation-state-generic:"arginine"
;[1628..1637]:variation-state-generic:"aspartate"
;[1715..1728]:variation-type:"substitutions"
(SENT
  (S
    (ADVP (RB:[1550..1557] However))
    (,:[1557..1558] ,)
    (NP-SBJ
      (NP (JJ:[1559..1566] certain)
        (NML (JJ:[1567..1572] amino) (NN:[1573..1577] acid))
        (NNS:[1578..1591] substitutions))
      (,:[1591..1592] ,)
      (PP (VBG:[1593..1602] including)
        (NP (NN:[1603..1611] cysteine) (,:[1611..1612] ,)
            (NN:[1614..1622] arginine) (,:[1622..1623] ,) (CC:[1624..1627] and)
            (NN:[1628..1637] aspartate))))
    (,:[1637..1638] ,)
    (VP (VBD:[1639..1648] indicated)
      (NP (DT:[1649..1650] a)
        (ADJP (RB:[1651..1664] significantly) (JJR:[1665..1671] poorer))
        (NN:[1672..1681] prognosis))
      (,:[1681..1682] ,)
      (SBAR-ADV (IN:[1683..1690] whereas)
        (S
          (NP-SBJ (JJ:[1692..1703] hydrophobic)
            (NML (JJ:[1704..1709] amino) (NN:[1710..1714] acid))
            (NNS:[1715..1728] substitutions))
          (VP (VBD:[1729..1735] showed)
            (NP
              (NP (DT:[1736..1737] a)
                (ADJP (RB:[1738..1751] significantly) (JJR:[1752..1758] better))
                (NN:[1759..1768] prognosis))
              (PP (IN:[1770..1774] than)
                (NP (JJ:[1775..1784] wild-type)))
              (PRN (-LRB-:[1785..1786] -LRB-)
                (S
                  (NP-SBJ (NN:[1786..1787] P))
                  (VP (SYM:[1788..1789] =)
                    (NP (CD:[1790..1794] 0.04))))
                (-RRB-:[1794..1795] -RRB-)))))))
    (.:[1795..1796] .)))

;sentence 16 Span:1797..1880
;Sample sizes were small for this analysis due to the  number of possible
;mutations.
(SENT
  (S
    (NP-SBJ (NN:[1797..1803] Sample) (NNS:[1804..1809] sizes))
    (VP (VBD:[1810..1814] were)
      (ADJP-PRD (JJ:[1815..1820] small))
      (PP (IN:[1821..1824] for)
        (NP (DT:[1825..1829] this) (NN:[1830..1838] analysis)))
      (PP-PRP (JJ:[1839..1842] due)
        (PP (TO:[1843..1845] to)
          (NP
            (NP (DT:[1846..1849] the) (NN:[1851..1857] number))
            (PP (IN:[1858..1860] of)
              (NP (JJ:[1861..1869] possible) (NNS:[1870..1879] mutations)))))))
    (.:[1879..1880] .)))

;sentence 17 Span:1881..1973
;As expected, the stage of tumor at resection was  the most significant
;predictor of outcome.
;[1907..1912]:malignancy:"tumor"
(SENT
  (S
    (SBAR-ADV (IN:[1881..1883] As)
      (S
        (NP-SBJ-1 (-NONE-:[1883..1883] *))
        (VP (VBN:[1884..1892] expected)
          (NP-1 (-NONE-:[1892..1892] *)))))
    (,:[1892..1893] ,)
    (NP-SBJ
      (NP (DT:[1894..1897] the) (NN:[1898..1903] stage))
      (PP (IN:[1904..1906] of)
        (NP (NN:[1907..1912] tumor)))
      (PP-TMP (IN:[1913..1915] at)
        (NP (NN:[1916..1925] resection))))
    (VP (VBD:[1926..1929] was)
      (NP-PRD
        (NP (DT:[1931..1934] the)
          (ADJP (RBS:[1935..1939] most) (JJ:[1940..1951] significant))
          (NN:[1952..1961] predictor))
        (PP (IN:[1962..1964] of)
          (NP (NN:[1965..1972] outcome)))))
    (.:[1972..1973] .)))

;section 18 Span:1974..2308
;Based on this study of 181 patients  from two major medical centers located
;in different cities, we conclude that  KRAS mutation status is not a
;satisfactory predictor of prognosis in lung  adenocarcinoma, but the
;substitution of a polar or charged amino acid for the  wild-type glycine
;residue may be a negative prognostic indicator.
;[2089..2093]:gene-rna:"KRAS"
;[2158..2178]:malignancy:"lung  adenocarcinoma"
;[2188..2200]:variation-type:"substitution"
;[2253..2260]:variation-state-original:"glycine"
(SEC
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[1974..1974] *))
      (VP (VBN:[1974..1979] Based)
        (NP (-NONE-:[1979..1979] *))
        (PP-CLR (IN:[1980..1982] on)
          (NP
            (NP (DT:[1983..1987] this) (NN:[1988..1993] study))
            (PP (IN:[1994..1996] of)
              (NP
                (NP (CD:[1997..2000] 181) (NNS:[2001..2009] patients))
                (PP (IN:[2011..2015] from)
                  (NP
                    (NP (CD:[2016..2019] two) (JJ:[2020..2025] major)
                        (JJ:[2026..2033] medical) (NNS:[2034..2041] centers))
                    (VP (VBN:[2042..2049] located)
                      (NP (-NONE-:[2049..2049] *))
                      (PP-LOC (IN:[2050..2052] in)
                        (NP (JJ:[2053..2062] different)
                            (NNS:[2063..2069] cities))))))))))))
    (,:[2069..2070] ,)
    (NP-SBJ (PRP:[2071..2073] we))
    (VP (VBP:[2074..2082] conclude)
      (SBAR (IN:[2083..2087] that)
        (S
          (S
            (NP-SBJ
              (NML (NN:[2089..2093] KRAS) (NN:[2094..2102] mutation))
              (NN:[2103..2109] status))
            (VP (VBZ:[2110..2112] is) (RB:[2113..2116] not)
              (NP-PRD
                (NP (DT:[2117..2118] a) (JJ:[2119..2131] satisfactory)
                    (NN:[2132..2141] predictor))
                (PP (IN:[2142..2144] of)
                  (NP (NN:[2145..2154] prognosis))))
              (PP (IN:[2155..2157] in)
                (NP (NN:[2158..2162] lung) (NN:[2164..2178] adenocarcinoma)))))
          (,:[2178..2179] ,) (CC:[2180..2183] but)
          (S
            (NP-SBJ
              (NP (DT:[2184..2187] the) (NN:[2188..2200] substitution))
              (PP (IN:[2201..2203] of)
                (NP (DT:[2204..2205] a)
                  (NML
                    (NML (JJ:[2206..2211] polar)
                      (NML-1 (-NONE-:[2211..2211] *P*)))
                    (CC:[2212..2214] or)
                    (NML (JJ:[2215..2222] charged)
                      (NML-1 (JJ:[2223..2228] amino) (NN:[2229..2233] acid))))))
              (PP (IN:[2234..2237] for)
                (NP (DT:[2238..2241] the) (JJ:[2243..2252] wild-type)
                    (NN:[2253..2260] glycine) (NN:[2261..2268] residue))))
            (VP (MD:[2269..2272] may)
              (VP (VB:[2273..2275] be)
                (NP-PRD (DT:[2276..2277] a) (JJ:[2278..2286] negative)
                        (JJ:[2287..2297] prognostic) (NN:[2298..2307] indicator))))))))
    (.:[2307..2308] .)))
;ERROR_Entity in section[2089..2093]:gene-rna "KRAS"
;ERROR_Entity in section[2158..2178]:malignancy "lung  adenocarcinoma"
;ERROR_Entity in section[2188..2200]:variation-type "substitution"
;ERROR_Entity in section[2253..2260]:variation-state-original "glycine"

;section 19 Span:2312..2356
;PMID: 9332768 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2312..2316] PMID) (::[2316..2317] :) (CD:[2318..2325] 9332768)
        (NN:[2326..2327] -LSB-) (NNP:[2327..2333] PubMed) (::[2334..2335] -)
        (NN:[2336..2343] indexed) (IN:[2344..2347] for)
        (NNP:[2348..2356] MEDLINE-RSB-)))
